Autopsy report · NCT03518112

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

“Due to Competing Studies”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 1 month before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia

Interventions

Blinatumomab; Cyclophosphamide; Cytarabine; Dexamethasone; Filgrastim; Laboratory Biomarker Analysis

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder
  “Competing studies” (89% match in meaning)
• Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
  “the study was closed early due to competing trials” (66% match in meaning)
• Radiation Use During Vemurafenib Treatment
  “Competing Trials” (63% match in meaning)
• Double-Lumen Tube Intubation in the Lateral Position Versus the Supine Position on First-Attempt Success Rate
  “Similar studies have been conducted” (62% match in meaning)
• Study of Dara-Pembro for Multiple Myeloma Patients
  “Low enrollment due to competing studies” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.